Circulating MicroRNA-26a in Plasma and Its Potential Diagnostic Value in Gastric Cancer

Xiaonan Qiu1,2, Jinyue Zhang3☯, Weihong Shi3☯, Sang Liu1,2, Meiyun Kang1,2, Haiyan Chu1,2, Dongmei Wu1,2, Na Tong1,2, Weida Gong4, Guoquan Tao5, Qinghong Zhao6, Fulin Qiang7, Haixia Zhu1,7, Qin Wu3*, Meilin Wang1,2*, Zhengdong Zhang1,2*

1 Department of Environmental Genomics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China, 2 Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China, 3 Department of Medical Technology, Yancheng Institute of Health Sciences, Yancheng, China, 4 Department of General Surgery, Yixing Cancer Hospital, Yixing, China, 5 Department of General Surgery, Huai-An First People’s Hospital Affiliated to Nanjing Medical University, Huai-An, China, 6 Department of General Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China, 7 Core Laboratory, Nantong Tumor Hospital, Nantong, China

☯ These authors contributed equally to this work.
* drzdzhang@gmail.com (ZZ); mwang@njmu.edu.cn (MW); hhwuq@163.com (QW)

Abstract

Background

In the past decades, a good deal of studies has provided the possibility of the circulating microRNAs (miRNAs) as noninvasive biomarkers for cancer diagnosis. The aim of our study was to detect the levels of circulating miRNAs in tissues and plasmas of gastric cancer (GC) patients and evaluate their diagnostic value.

Methods

Tissue samples were collected from 85 GC patients. Plasma samples were collected from 285 GC patients and 285 matched controls. Differentially expressed miRNAs were filtered with by Agilent Human miRNA Microarray and TaqMan low density array (TLDA) with pooled samples, followed by the quantitative reverse transcription polymerase chain reaction (qRT-PCR) validation. Receiver operating characteristic (ROC) curves were structured to evaluate the diagnostic accuracy of the miRNAs. The plasma level of miR-26a in GC patients of different clinical stages was compared.

Results

Four miRNAs (miR-26a, miR-142-3p, miR-148a, and miR-195) revealed coincidentally decreased levels in tissue and plasma of the GC patients compared with controls, and ROC curves were constructed to demonstrate that miR-26a had a highest area under the ROC curve (AUC) of 0.882. Furthermore, miR-26a was stably detected in the plasma of GC patients with different clinical characteristics.
Conclusion
Plasma miR-26a may provide a novel and stable marker of gastric cancer.

Introduction
Gastric cancer (GC) is one of the most common malignancies in the world. Although the overall incidence has declined in the recent years, it is the fourth most common malignancy (989,000 cases) and the second leading cause of cancer-related death (738,000 deaths) worldwide [1]. More than 70% of cases occur in developing countries [2]. In particular, advanced-stage patients still demonstrate extremely poor survival rates [3]. To date, the diagnosis of GC is based on the clinical symptoms, and there are some test techniques applied such as endoscopy, and barium meal examination. However, all of these approaches have shown some defects at detection of GC. In addition, there are some serum tumor markers for instance carcinoembryonic antigen (CEA), carbohydrate antigen 19–9 (CA19-9) and carbohydrate antigen 72–4 (CA72-4), and there are some limitations of the sensitivity and specificity for GC screening [4]. Hence, we pay more attention on discovering novel, dependable and noninvasive biomarkers of GC.

MicroRNAs (miRNAs) are a class of short (20~25 nucleotides), noncoding single-stranded RNAs [5]. It is widely believed that miRNAs can participate in regulating gene expression, giving rise to mRNA silencing such as target cleavage, translational inhibition, and mRNA decay [6]. Accumulating evidence has indicated that miRNAs were involved in several pathophysiological processes and lead to fundamental changes in multiple diseases. Zhang et al. found that miR-26a induced endothelial apoptosis and indicated a therapeutic potential of miR-26a for atherosclerosis associated with apoptotic cell death [7]. Leonov et al. described inhibition of miR-132 resulted in high AGO2 expression, which was involved in angiogenesis and inflammation during primary endothelial cell activation [8]. Numerous studies have indicated that the miRNAs play indispensable roles on tumorigenesis, acting either as oncogenes or tumor suppressor genes [9]. Several miRNAs have reported to be related to cancer by the miRNA expression profiles [10–12]. Unfortunately, the tissue samples are difficult to acquire. Detecting miRNAs in tissues is not realistic in clinical application.

Moreover, increasing evidence has demonstrated that circulating miRNAs are resistant to RNase digestion and stably detectable in plasma and serum with ease of measurements [13–14]. Previous studies have confirmed that the existence of miRNAs in blood and the expression associated with cancer, including large B-cell lymphoma, colorectal cancer, bladder cancer and breast cancer [15–18]. These studies collectively provide a basis for circulating miRNAs acting as novel biomarkers for cancer screening.

Many studies demonstrate the expression level of miRNA in plasma is not completely consistent with that in tumor. miR-378 declined significantly in GC tissue and several cell lines [19], but miR-378 were meaningfully up-regulated in GC patients’ serum [20]. As the same as miR-486, miR-486 may function as a tumor-suppressor miRNA in gastric tumor [21], which were overexpressed in the GC patients’ serum [22]. At the present, several serum/plasma miRNAs can distinguish from the GC patients with the controls, nevertheless this can’t represent the miRNA expression in tissue. If we can find out the miRNAs both differentially expressed in gastric cancer tissue and plasma, it should have more clinical significance.

To ascertain whether the miRNAs differentially expressed both in tissue and plasma, we used two microarrays to screen miRNAs. In the two validation stages, four candidate miRNAs were significantly down-regulated in the tumor tissues and plasma samples by qRT-PCR. Our
study indicated that miR-26a was significantly decreased stably in plasma of gastric cancer patients and could distinguish gastric cancer patients from controls, with good sensitivity and specificity. It was predicted to be a promising circulating biomarker of gastric cancer in routine clinical diagnosis.

**Materials and Methods**

**Study design and subjects**

This study was authorized by the institutional review board of Nanjing Medical University, and each participant provided the signed written informed consent. All of the subjects were recruited at Yixin Cancer Hospital, Nantong Tumor Hospital, Huai-An First People's Hospital and The Second Affiliated Hospital of Nanjing Medical University from March 2006 to May 2013 in Jiangsu province, China.

The tumor tissues and the normal tissues (located > 5 cm away from the tumor) were obtained from 55 GC patients undergoing surgery and snap-frozen in liquid nitrogen. The plasma samples were collected from 285 GC patients, and 285 sex- and age-matched plasma from the healthy individuals were collected as the controls. All patients were proven the histologically diagnosis of GC at initial diagnosis, and none of them had received therapeutic procedures, for instance chemotherapy or radiotherapy. We classified the tumor stage in accordance with the tumor-node-metastasis (TNM) staging system of the Union for International Cancer Control (UICC). The clinical characteristics of study participants are presented in Table 1.

A multi-stage study was designed to identify the plasma miRNAs as the biomarkers for GC patients (Fig 1). In the discovery stage, differentially expressed miRNAs were assessed in the paired tissue samples from 5 GC patients (S1 Table) by Agilent Human miRNA Microarray (V12.0, Agilent Technology, CA, USA). Plasma samples from 5 GC patients (S2 Table) whose sex, age clinical states matched with the tissue samples and 5 healthy controls were subjected to TLDA (V2.0; Applied Biosystems, Foster city, CA, USA) to identify the differentially expressed miRNAs. In the training phase, the significantly altered miRNAs were first evaluated by qRT-PCR in 50 paired tissues samples and 80 GC serum samples and 80 matched controls. Subsequently, the differentially expressed miRNAs between the tissue and serum were further examined in additional 400 participants, which included 200 GC patients and 200 controls.

**RNA isolation from plasma and tissue**

Blood samples in the separate vacuum cubes were centrifuged at 3,000 rpm for 10 min at 4°C. We collected the supernatant and stored them at -80°C. Before starting the isolation procedure, we added a final concentration of 10⁻⁴ pmol/μl of synthetic *C. elegans* miR-39 (cel-miR-39) (Takara, Japan) to each sample, in order to controlling the biological variability. The RNA was extracted from 100 μl of plasma using QIAGEN miRNeasy Mini Kit (Qiagen, Valencia, CA, USA). The total RNA of tissues was isolated using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA).

**Microarrays and qRT-PCR**

Profiling was carried out using Agilent Human miRNA Microarray (V12.0, Agilent Technology, CA, USA) and TaqMan low-density array (V2.0; Applied Biosystems, Foster City, CA, USA). For the total RNA isolating from tissues, qRT-PCR was performed using SYBR(R) PrimeScript™ RT-PCR Kit (Takara Bio). A detailed description of the experimental protocols is deposited in the S1 Data.
Statistical analyses

The paired tissue samples were compared using a Wilcoxon rank sum test. Non-parametric Mann-Whitney U test was performed to determine the significance in plasma miRNA levels between the cancer group and healthy group. Receiver-operator characteristic (ROC) curves and the areas under the ROC curves (AUCs) were obtained to assess the GC detection potential of miRNAs. Statistical analyses were two-sided test, and $P < 0.05$ was considered statistically significant. All the statistical analyses were performed with SPSS software version 16.0 (SPSS Inc., Chicago, IL, USA).

Table 1. Clinical characteristics of subjects.

| Variables                  | The paired tissue samples (n = 50) | The plasma samples |
|----------------------------|-----------------------------------|--------------------|
|                            | N (%)                             | N (%)              | N (%)              | P      |
| Age (years)                | N (%)                             | N (%)              | N (%)              | P      |
| Mean ± SD                  | 64.79 ± 11.28                     | 63.27 ± 9.90       | 63.23 ± 9.88       | 0.977a |
| ≤ 65 years                 | 25 (50.0)                         | 149 (53.2)         | 149 (53.2)         | 0.534a |
| > 65 years                 | 25 (50.0)                         | 131 (46.8)         | 131 (46.8)         |        |
| Gender                     | Male                              | 37 (74.0)          | 177 (63.2)         | 0.535b |
|                            | Female                            | 13 (26.0)          | 103 (36.8)         |        |
| Lauren’s types             | Intestinal                        | 27 (54)            | 126 (45.0)         |        |
|                            | Diffuse                           | 22 (44)            | 149 (53.2)         |        |
|                            | Missing                           | 1 (2)              | 5 (1.8)            |        |
| Invasion depth             | T1                                | 3 (6.0)            | 45 (16.1)          |        |
|                            | T2                                | 6 (12.0)           | 40 (14.3)          |        |
|                            | T3                                | 26 (52.0)          | 172 (61.4)         |        |
|                            | T4                                | 15 (30.0)          | 17 (6.1)           |        |
|                            | Missing                           | 1 (2)              | 6 (2.1)            |        |
| Lymph nodes metastasis     | No                                | 13 (26.0)          | 97 (34.6)          |        |
|                            | Yes                               | 37 (74.0)          | 176 (62.9)         |        |
|                            | Missing                           | -                  | 7 (2.5)            |        |
| Distant metastasis         | No                                | 38 (76.0)          | 263 (93.9)         |        |
|                            | Yes                               | 12 (24.0)          | 14 (5)             |        |
|                            | Missing                           | -                  | 3 (1.1)            |        |
| TNM stage                  | I                                 | 6 (12.0)           | 65 (23.2)          |        |
|                            | II                                | 13 (26.0)          | 61 (21.8)          |        |
|                            | III                               | 17 (34.0)          | 135 (48.2)         |        |
|                            | IV                                | 14 (28.0)          | 16 (5.7)           |        |
|                            | Missing                           | -                  | 3 (1.1)            |        |

$a$ Student’s t test

$b$ Two-sided χ² test

doi:10.1371/journal.pone.0151345.t001
**Screening phase:** miRNA microarray analysis  
Agilent Human miRNA Microarray & TaqMan low density array

Selection criteria: the expression deregulation in cancer tissue  
consistent with TLDA result and fold change ≥ 2

**Training phase:** qRT-PCR training set on individual samples (50 paired tissue samples and plasma samples 80 cases vs. 80 controls)

miRNAs have mean fold change ≥ 2, $P$ value < 0.01 and Ct value < 35

**Validation phase:** qRT-PCR validation set on individual plasma samples (200 cases vs. 200 controls)

miRNAs have mean fold change ≥ 2 and $P$ value < 0.01

**Evaluation phase:** the ROC curve analyses provide miR-26a as a unique non-invasive biomarker for GC

---

**Results**

**Discovery of candidate biomarkers by microarrays**

We used two microarray platforms for the miRNAs to analyze and compare the miRNA expression patterns from two different conditions. TLDA analysis was completed to confirm candidate miRNAs expression levels. A total of 142 miRNAs were detected in plasma. 65 of the total miRNAs were increased and 77 were decreased in GC patients compared with controls.
To identify candidate miRNAs, the expression of miRNAs between patients and controls were necessary to correspond with two criteria: (1) the expression deregulation in tumor tissue was consistent with TLDA outcome[23]; and (2) the plasma miRNA levels proving ≥ 2-fold difference between patients and controls. Ultimately, four down-regulated plasma miRNAs (i.e., miR-26a, miR-142-3p, miR-148a and miR-195) were selected as the candidates for the fist-stage validation (Table 2).

**Confirmation of miRNAs by qRT-PCR**

Firstly, the results of microarrays analyses were confirmed using the paired tissues, the GC plasma and the matched controls for these four miRNAs by qRT-PCR. Our results demonstrated that the tendency of the results of qRT-PCR was similar to the microarrays analyses, either in tissues or in plasma. The plot showed that the expression levels of four miRNAs were statistically significant in the GC tissues (P = 0.001, P = 0.002, P < 0.001 and P = 0.003 for miR-26a, miR-142-3p, miR-148a and miR-195, respectively, Figs 2A–2D). In the meantime, we performed qRT-PCR to verify the expressions of miRNAs were down-regulated in another independent set of 80 GC plasma samples and 80 healthy controls. The expressions of four miRNAs in GC plasma were significantly decreased compared to those in controls (all P < 0.001, Figs 2E–2H). The expressions levels of the four miRNAs in plasma were consistently decreased, comparing with tissue samples.

**Large-scale validation of the plasma microRNAs in GC patients**

In order to validate stability of the plasma expressions of miRNAs, we performed qRT-PCR in a large scale of 200 GC plasma samples and 200 matched cancer-free controls. Accordant with the results of the training phase, the expression levels of four miRNAs showed significant down-regulation in plasma of GC patients (all P < 0.001, Fig 3), suggesting that these four miRNAs in plasma may serve as the candidate biomarkers for diagnosis of GC.

| miRNAs       | Agilent Human miRNA Microarray | TaqMan low density array |
|--------------|-------------------------------|--------------------------|
|              | Ct                            | Fold change              | CasesΔCta | ControlsΔCt | ΔΔCtb          |
| hsa-miR-99a  | -                             | 2.034623                 | 11.60988  | 13.53345    | -1.92357       |
| hsa-miR-17   | -                             | 3.120369                 | 2.98488   | 4.20745     | -1.22257       |
| hsa-miR-199a-3p | -                          | 2.066154                 | 8.43588   | 9.13345     | -0.69757       |
| hsa-miR-483-5p | -                           | 2.006861                 | 7.67088   | 8.21245     | -0.54157       |
| hsa-miR-18a  | -                             | 4.948928                 | 9.67688   | 10.13345    | -0.45657       |
| hsa-miR-27b  | -                             | 0.628604                 | 12.52188  | 12.09045    | 0.43143        |
| hsa-miR-145  | -                             | 0.6572                   | 10.60988  | 9.88745     | 0.72243        |
| hsa-miR-375  | -                             | 0.333354                 | 12.18088  | 11.02345    | 1.15743        |
| hsa-miR-215  | -                             | 0.470013                 | 13.95988  | 12.30445    | 1.65543        |
| hsa-miR-148a | -                             | 0.564722                 | 11.02288  | 8.98245     | 2.04043        |
| hsa-miR-142-3p | -                           | 0.577768                 | 9.70188   | 7.58945     | 2.11243        |
| hsa-miR-26a  | -                             | 0.679287                 | 10.71788  | 7.95645     | 2.76143        |
| hsa-miR-195  | -                             | 0.562931                 | 14.94188  | 10.08245    | 4.85943        |

*ΔCt = Ct_sample–Ct_Cal-39*

*ΔΔCt = ΔCt_case – ΔCt_control*

doi:10.1371/journal.pone.0151345.t002
Fig 2. Box plots of relative expression levels of miRNAs by qRT-PCR in the training phases. (A-D) Relative expression levels of miR-26a, miR-142-3p, miR-148a, miR-195, in 50 paired gastric cancer tissues and corresponding noncancerous tissues (log10 scale on Y-axis). (E-H) Plasma expression levels of miR-26a, miR-142-3p, miR-148a, miR-195, in 80 GC patients and 80 healthy controls. The lines inside the boxes denote the medians (log10 scale on Y-axis). The whiskers of box plots: Min to Max.

doi:10.1371/journal.pone.0151345.g002
To assess the efficiency of above four miRNAs as diagnostic markers for GC detection, we performed ROC curve analysis on each miRNA. Fig 4 revealed that the ROC curves of four candidate miRNAs demonstrated the plasma miRNAs were of value to distinguish GC patients from normal controls. The cutoff value of 0.651 was equal to sensitivity + specificity - 1 which was maximal for miR-26a (relative expression normalized by cel-39). For miR-26a, the sensitivity was 83.6% and the specificity was 81.5% with an AUC of 0.882 (95% CI = 0.847–0.916) (Fig 4A). At the cut-off value of 0.585 for miR-142-3p, the sensitivity was 74.4% and the specificity was 84.1% with an AUC of 0.839 (95% CI = 0.800–0.879) (Fig 4B). The AUCs were 0.842 (95%...
CI = 0.803–0.882) and 0.765 (95% CI = 0.717–0.812) for miR-148a and miR-195, respectively. The sensitivity and specificity were 75.4% and 83.1% for miR-148a, 69.2% and 75.4% for miR-195, respectively (Fig 4C and 4D). The combination ROC curve analysis yielded the AUC value of 0.872 (95% CI = 0.836–0.908) (Fig 4E).

To verify the diagnosis value of the host miRNA for GC, we combined any of the plasma miRNAs and performed the ROC curves as shown in S1 and S2 Figs. These data indicated that the miR-26a which showed the greatest ability for differentiating the GC patients from controls, could act as a suitable biomarker for detecting GC.

Discussion

In spite of a significant decline in GC mortality in the past decade, the mortality rate is still higher than many other common malignancies [24]. In recent years, the tumor biomarkers for instance CEA, CA19-9, CA74-2 with the limited sensitivity and specificity have been widely used for diagnosis, monitoring and prognosis of GC [4]. All in all, there is of great significance for diagnosis of GC to look for more specific and sensitive biomarkers.

Tissue miRNAs as the biomarkers of diagnosis and prognosis were first proposed. Bandres et al. revealed that miR-451 was down-regulated in primary gastric and colorectal tumors, and the down-regulation of miR-451 was associated with low DFS and low overall survival [25]. Xiao et al. identified miR-106a as a dramatically up-regulated miRNA in GC [26]. They also

![ROC curve analysis using four miRNAs for discriminating GC patients from healthy controls.](doi:10.1371/journal.pone.0151345.g004)
found that the expression of miR-106a was significantly related to tumor stage, lymphatic, distant metastasis and invasion. Nonetheless, many types of cancer patients have been unable to undergo surgery in clinical practice when they are diagnosed. The reliance on surgical section and invasive procedure for tissue sample collection strongly limited the application of miRNAs in tissue of cancer diagnosis [27]. The diagnostic quality of these methods is unsatisfactory.

Emerging evidence also implies that circulating miRNAs are related to cancer [28–30]. The recent study reported that the miRNAs were detectable in plasma and stable at room temperature and/or multiple freezing-thawing processes [31]. Numerous reports had illuminated that the usefulness of circulating miRNAs as novel noninvasive biomarkers for cancers, such as colorectal cancer [32], breast cancer [33–34] and renal cell carcinoma [35].

In our study, we methodically screened the miRNA profile in the paired tissues and in plasma from GC patients and healthy controls. Plasma obtained from 5 cases and 5 controls were mixed together to form two pooled samples and were used for TLDA. This method of pooling samples is a widely used technique that has been shown to be reliable for profiling [36–38]. Comparing TLDA analysis and the result of tissue microarray, four miRNAs (miR-26a, miR-142-3p, miR-148a and miR-195) reduced in GC were selected.

Subsequently, we identified four candidate miRNAs by qRT-PCR in two stages, and found the expression levels of four miRNAs slumped in the plasma of GC patients which were in agreement with the expressions in tissues. ROC curve, also known as sensitivity curve, is widely recognized as an evaluation method of diagnostic test. It is also an integrated indicator reflecting the sensitivity and specificity of continuous variables. In the current study, ROC analysis indicated that the combination of four miRNAs wasn’t more effective than miR-26a individually. MiR-26a alone could achieve a good diagnostic efficiency in distinguishing GC patients from healthy controls with an AUC of 0.882 (sensitivity = 83.6% and specificity = 81.5%). A previous study by Schneider et al. displayed the serum levels of CEA, CA19-9 and CA72-4 in GC elucidated a sensitivity of 45.5% for CA19-9, 23.8% for CEA and 60.7% for CA72-4 [39]. These were far less than the sensitivity of miR-26a. Furthermore, the expression level of miR-26a in plasma was significant lower in the GC patients, and didn’t show any significance with the progression of GC (S3 Fig). Hence, miR-26a had great potential as a diagnostic plasma biomarker for GC.

In the past decades, the previous studies didn’t verify that whether the miRNA expression of plasma or serum could represent the levels of tissue. Compared with these studies, our study had own feature owing to reasons as follows. First, we selected the miRNAs which expressed differentially both in tissue and plasma, by comparing the results of two microarrays. This resulted in a better opportunity to identify feasible diagnostic markers. Furthermore, we found that the miR-26a expression significantly reduced in GC patients and kept stable in the plasma (S3 Fig).

The results revealed that the plasma expression of miR-26a was significant lower in the GC patients compared with the healthy controls ($P < 0.05$), which showed stability in GC patients with different clinical status. The down-regulation of plasma miR-26a expression may indicate the probability of diagnosing GC. Therefore, miR-26a may be a best choice to serve as potential biomarker for GC. Deng et al. showed that miR-26a levels in GC tissues were more remarkably decreased than those in non-tumor tissues by qRT-PCR [40]. They also demonstrated that miR-26a inhibited tumor growth and metastasis partly by targeting FGF9 in vivo. These consisted with our results. These findings confirmed that miRNA-26a in plasma could be a potential diagnostic marker for GC.

However, the limitations of our study are that the samples for the tissue microarray and for the TLDA were not from the same patients, and our sample sizes for the microarrays were relative small. Further analysis of the microarrays for the same patients and the enlarged-sample
confirmation are required to be applied as a novel screening tool for GC in the routine clinical utilization. Additionally, we didn’t choose the up-regulated miRNAs because of the fact that there were not the up-regulated miRNAs whose fold changes were ≥ 2. We selected candidate miRNAs which were profusely expressed in plasma to make sure of the probability of examination in clinical practice.

Conclusions
In summary, our study revealed four down-regulated miRNAs, miR-148a, miR-142-3p, miR-26a, and miR-195, in GC patients. More importantly, the plasma expression of miR-26a was significantly reduced and stable in patients with gastric cancer. As a result, miR-26a may provide a non-invasive and stable biomarker of gastric cancer diagnosis and screening.

Supporting Information
S1 Data. Experimental Protocols of Microarrays and qRT-PCR.
(DOC)

S1 Fig. ROC curve analysis of the combination of two miRNAs among the four candidate miRNAs. The combination of miR-26a and miR-142-3p (A), the combination of miR-26a and miR-148a (B), the combination of miR-26a and miR-195 (C), and the combination of miR-142-3p and miR-148a (D), the combination of miR-142-3p and miR-195(E) and the combination of miR-148a and miR-195 (F) yielded the largest AUCs.
(DOC)

S2 Fig. ROC curve analysis of the combination of three miRNAs among the four candidate miRNAs. The combination of miR-26a, miR-142-3p and miR-148a (A), the combination of miR-26a, miR-142-3p and miR-195 (B), the combination of miR-26a, miR-148a and miR-195 (C) and the combination of miR-142-3p, miR-148a and miR-195 (D) yielded the largest AUCs.
(DOCX)

S3 Fig. Plasma level of miR-26a in gastric cancer patients stratified by the clinical status. Box plots showed the plasma levels of miR-26a in 200 healthy controls and 200 gastric cancer patients at different clinical status.
(DOCX)

S1 Table. Clinical characteristics of tissue subjects screening by Agilent Human miRNA Microarray.
(DOC)

S2 Table. Clinical characteristics of plasma subjects screening by TLDA.
(DOC)

Acknowledgments
We are deeply grateful for the participation of all subjects contributing to this research.

Author Contributions
Conceived and designed the experiments: ZZ MW QW. Performed the experiments: XQ JZ WS SL. Analyzed the data: MK SL. Contributed reagents/materials/analysis tools: HC DW NT. Wrote the paper: XQ JZ WS SL. Contributed samples: WG GT QZ FQ HZ. Revised the manuscript critically: ZZ MW QW.
11. Habbe N, Koorstra JB, Mendell JT, Offerhaus GJ, Ryu JK, Feldmann G, et al. MicroRNA miR-155 is a
10. Ai J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, et al. Circulating microRNA-1 as a potential novel biomarker for
gastric cancer. Lancet. 2009; 374(9688):477–90. doi: 10.1016/S0140-6736(09)60617-6 PMID: 19625077

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61(2):69–90. doi: 10.3322/caac.20107 PMID: 21296895
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal international du cancer. 2010; 127(12):2893–917. doi: 10.1002/ijc.25516 PMID: 21351269
3. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009; 374(9688):477–90. doi: 10.1016/S0140-6736(09)60617-6 PMID: 19625077
4. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Haglund C. CEA, CA 19–9 and CA 72–4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer research. 2002; 22(4):2311–6. PMID: 12174919
5. Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009; 136(6):642–55. doi: 10.1016/j.cell.2009.01.035 PMID: 19239886
6. Winter J, Diederichs S. MicroRNA biogenesis and cancer. Methods Mol Biol. 2011; 676:3–22. doi: 10.1007/978-1-60761-863-8_1 PMID: 20931386
7. Zhang Y, Qin W, Zhang L, Wu X, Du N, Hu Y, et al. MicroRNA-26a prevents endothelial cell apoptosis by directly targeting TRPC6 in the setting of atherosclerosis. Sci Rep. 2015; 5:9401. doi: 10.1038/srep09401 PMID: 25801675
8. Leonov G, Shah K, Yee D, Timmis J, Sharp TV, Lagos D. Suppression of AGO2 by miR-132 as a determinant of miRNA-mediated silencing in human primary endothelial cells. Int J Biochem Cell Biol. 2015; 69:75–84. doi: S1357-2725(15)30033-9 [pii] doi: 10.1016/j.biocel.2015.06.006 PMID: 26475020
9. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nature reviews Genetics. 2009; 10(10):704–14. doi: 10.1038/nrg2634 PMID: 19763153
10. Ai J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochemical and biophysical research communications. 2010; 391(1):73–7. doi: 10.1016/j.bbrc.2009.11.005 PMID: 19896465
11. Habbe N, Koorstra JB, Mendell JT, Offerhaus GJ, Ryu JK, Feldmann G, et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer biology & therapy. 2009; 8(4):2311–2317. doi: 10.1016/j.canlet.2011.10.034 PMID: 22169097
12. Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer research. 2008; 68(24):10307–14. doi: 10.1158/0008-5472.CAN-08-1954 PMID: 19074899
13. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell research. 2008; 18(10):997–1006. doi: 10.1038/cr.2008.282 PMID: 18766170
14. Ichikawa D, Komatsu S, Konishi H, Otsuji E. Circulating microRNA in digestive tract cancers. Gastroenterology. 2012; 142(5):1074–81 e1. doi: 10.1053/j.gastro.2012.03.008 PMID: 22433992
15. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. MicroRNA microarray identifies genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of breast cancer. International journal of cancer Journal international du cancer. 2014. doi: 10.1002/ijc.29041 PMID: 24961907
16. Ng EK, Chong WW, Jin H, Lam EM, Shing VY, Yu J, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009; 58(10):1375–81. doi: 10.1136/gut.2008.167817 PMID: 19201770
17. Jiang X, Du L, Wang L, Li J, Liu Y, Zheng G, et al. Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer. International journal of cancer Journal international du cancer. 2014. doi: 10.1002/ijc.29041 PMID: 24961907
18. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Annals of surgery. 2010; 251(3):499–505. doi: 10.1097/SLA.0b013e3181cc939f PMID: 20134314
19. Fei B, Wu H. MiR-378 inhibits progression of human gastric cancer MGC-803 cells by targeting MAPK1 in vitro. Oncology research. 2012; 20(12):557–64. doi: 10.3727/096504013X13775486749254 PMID: 24139413
20. Liu H, Zhu L, Liu B, Yang L, Meng X, Zhang W, et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer letters. 2012; 316(2):196–203. doi: 10.1016/j.canlet.2011.10.034 PMID: 22169097
21. Oh HK, Tan AL, Das K, Ooi CH, Deng NT, Tan IB, et al. Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(2):457–67. doi: 10.1158/1078-0432.CCR-10-0716 PMID: 21245692
journal of the American Association for Cancer Research. 2011; 17(9):2657–67. doi: 10.1158/1078-0432.CCR-10-3152 PMID: 21415212

22. Zhu C, Ren C, Han J, Ding Y, Du J, Dai N, et al. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. British journal of cancer. 2014; 110(9):2291–9. doi: 10.1038/bjc.2014.119 PMID: 24595006

23. Wang S, Lv C, Jin H, Xu M, Kang M, Chu H, et al. A common genetic variation in the promoter of miR-107 is associated with gastric adenocarcinoma susceptibility and survival. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 2014; 769:35–41. doi: 10.1016/j.mrfmmm.2014.07.002 PMID: 25771723

24. Brenner H, Rothenbacher D, Amdt V. Epidemiology of stomach cancer. Methods Mol Biol. 2009; 472:467–77. doi: 10.1007/978-1-60327-492-0_23 PMID: 19107449

25. Bandres E, Bitarte N, Arias F, Agorreta J, Fortes P, Agirre X, et al. microRNA-451 regulates macro-phase migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15(7):2281–90. doi: 10.1158/1078-0432.CCR-08-1818 PMID: 19318487

26. Xiao B, Guo J, Miao Y, Jiang Z, Huan R, Zhang Y, et al. Detection of miR-106a in gastric carcinoma and its clinical significance. Clinica chimica acta: international journal of clinical chemistry. 2009; 400(1–2):97–102. doi: 10.1016/j.cca.2008.10.021 PMID: 18996365

27. Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clinical chemistry. 2012; 58(3):610–8. doi: 10.1373/clinchem.2011.172767 PMID: 22194634

28. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of miRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature cell biology. 2007; 9(6):654–9. doi: 10.1038/ncb1596 PMID: 17486113

29. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(1):4402–7. doi: 10.1073/pnas.0813371106 PMID: 19246379

30. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(12):5003–8. doi: 10.1073/pnas.1019055108 PMID: 21383194

31. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(30):10513–8. doi: 10.1073/pnas.0804549105 PMID: 18663219

32. Nonaka R, Nishimura J, Kagawa Y, Osawa H, Hasegawa J, Murata K, et al. Circulating miR-199a-3p as a novel serum biomarker for colorectal cancer. Oncology reports. 2014. doi: 10.3892/or.2014.3515 PMID: 25269744

33. Mar-Aguilar F, Mendoza-Ramirez JA, Malagon-Silva PK, Santuario-Facio SK, Ruiz-Flores P, et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Disease markers. 2013; 34(9):163–9. doi: 10.3233/DMA-120957 PMID: 23394650

34. Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H, et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. Journal of cancer research and clinical oncology. 2013; 139(2):223–9. doi: 10.1007/s00432-012-1315-y PMID: 23052693

35. Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, Lakomy R, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. Journal of translational medicine. 2012; 10:55. doi:10.1186/1479-5876-10-55 PMID: 22440013

36. Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, et al. A five-microRNA signature identified from genomewide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer. 2011; 47(7):184–91. doi: 10.1016/j.ejca.2010.10.025 PMID: 21121772

37. Hu Z, Dong J, Wang LE, Ma H, Liu J, Zhao Y, et al. Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis. 2012; 33(4):828–34. doi: 10.1093/carcin/bgs030 PMID: 22298638

38. Takei Y, Takigahira M, Mihiwa K, Tanuma Y, Yanagihara K. The metastasis-associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer. Cancer research. 2011; 71(4):1442–53. doi: 10.1158/0008-5472.CAN-10-2530 PMID: 21169410

39. Schneider J, Schultze G. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19–9 and CA 72–4 in the diagnosis of gastrointestinal cancer. Anticancer research. 2003; 23(6D):5089–93. PMID: 14981971
40. Deng M, Tang HL, Lu XH, Liu MY, Lu XM, Gu YX, et al. miR-26a suppresses tumor growth and metastasis by targeting FGF9 in gastric cancer. PloS one. 2013; 8(8):e72662. doi: 10.1371/journal.pone.0072662 PMID: 24015269